Nexium approved for children
AstraZeneca's Nexium (esomeprazole magnesium) has received approval by the Food and Drug Administration (FDA) for the short-term treatment of gastroesophageal reflux disease in children ages 1 to 11.
AstraZeneca's Nexium (esomeprazole magnesium) has received approval by the Food and Drug Administration (FDA) for the short-term treatment of gastroesophageal reflux disease in children ages 1 to 11.
The approved dosage is 10 mg or 20 mg daily, in the form of a delayed-release capsule or a liquid. Pediatric patients 12 to 17 years of age can take 20 mg or 40 mg daily, which is already approved.
The FDA approved Nexium based upon safety and pharmacokinetic studies performed in pediatric patients, as well as the extrapolation of data from the results of studies in adults to the pediatric population.
Nexium belongs to a class of drugs known as proton-pump inhibitors (PPIs). PPIs help heal erosions in the lining of the esophagus (erosive esophagitis) by decreasing the amount of acid produced in the stomach.
Major congenital malformations not linked to first trimester tetracycline use
November 22nd 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
